FindTrial
Sign In

Clinical Study of Iguratimod in the Treatment of Primary Sjogren's Syndrome

Clinical Study of Iguratimod in the Treatment of Primary Sjogren's Syndrome

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900024642
Enrollment
Unknown
Registered
2019-07-19
Start date
2019-08-01
Completion date
Unknown
Last updated
2019-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Sjogren's Syndrome

Interventions

Experimental group:Iguratimod+Prednisone
control group:HCQ+Prednisone

Sponsors

Chongqing Hospital of Traditional Chinese Medcine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Complying with the International Classification Standard of Primary Sjogren's Syndrome revised by ACR/EULAR in 2016; (2) Aged from 18 to 65 years; (3) Understand the purpose and steps of the experiment and sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) Secondary Sjogren's syndrome; (2) Complicated with other connective tissue diseases, lymphoma, AIDS, sarcoidosis, graft-versus-host disease and advanced lymphoid tissue proliferation; (3) Patients with serious primary diseases such as cardiovascular, liver, kidney and hematopoietic system; (4) Pregnancy, lactation women, allergic constitution; (5) Used DMARDs drugs within 3 months before admission; (6) Psychiatric patients and others who can not cooperate.

Design outcomes

Primary

MeasureTime frame
ESSPRI score;ESSDAI score;ESR;CRP;Ig;—

Countries

China

Contacts

Public ContactQin Shao

Chongqing Hospital of Traditional Chinese Medicine

qinshao2011@126.com+86 15923915463

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026